Agnès Boyer-Chammard

Author

Also Known As

A BOYERCHAMMARD, A Boyer-Chammard, A. Boyer-Chammard, A. Boyer‐Chammard, Agnes Boyer-Chammard, Agnes Boyer‐Chammard, Agnès Boyer-Chammard, Agnès Boyer-chammard, Agnés Boyer-Chammard, Boyer-Chammard Agnès

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Innate Pharma (France)Centre Oscar Lambret Institut Gustave Roussy Assistance Publique Hôpitaux de Marseille Centre Léon Bérard

About

Agnès Boyer-Chammard is an author at Innate Pharma (France) specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	169
2	Language Studies	1	1	98
3	Blood Transplantation	1	1	98
4	Classics	1	1	98
5	French	1	1	98

Agnès Boyer-Chammard

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Outcome of Cord-Blood Transplantation from Related and Unrelated Donors Éliane Gluckman, Vanderson Rocha, Agnès Boyer-Chammard, New England Journal of Medicine	1997	1.3K
Survival Differences in Breast Cancer among Racial/Ethnic Groups: A Population-Based Study Agnès Boyer-Chammard, Thomas H. Taylor, Hoda Anton‐Culver Cancer Detection and Prevention	1999	115
Outcome of Cord-Blood Transplantation From Related and Unrelated Donors Éliane Gluckman, Vanderson Rocha, Agnès Boyer-Chammard, Obstetrical & Gynecological Survey Translation StudiesHistorical MethodologyTransplantationFrenchClaude Author Information	1998	98
Randomized study of 2 reduced‐intensity conditioning strategies for human leukocyte antigen‐matched, related allogeneic peripheral blood stem cell transplantation Didier Blaise, Reza Tabrizi, Jean‐Marie Boher, Cancer	2012	79
Cost-Effectiveness of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications Patricia Marino, Gilles Houvenaeghel, Fabrice Narducci, International Journal of Gynecological Cancer	2015	50
Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors. Roger B. Cohen, Jessica R. Bauman, Sébastien Salas, Journal of Clinical Oncology ImmunologyImmunoeditingPathologyPharmacotherapyMetronomic Chemotherapy	2020	40
Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial Didier Blaise, Raynier Devillier, A.-G. Lecoroller-Sorriano, Haematologica	2014	33
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])* Julien Carvelli, Ferhat Meziani, Jean Dellamonica, Critical Care Medicine	2022	26
Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data Romain Cohen, G. Lefebvre, Marshall R. Posner, Annals of Oncology Neck CancerOncologyMedicinePathologyImmune Checkpoint Inhibitor	2019	18
Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy Roger B. Cohen, Jérôme Fayette, Marshall R. Posner, Cancer Research Abstract Background MonalizumabImmunologyImmune RegulationPathologyPhase Ii Study	2018	13

Page 1